FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017990112> ?p ?o ?g. }

• W2017990112 endingPage "1242" @default.
• W2017990112 startingPage "1234" @default.
• W2017990112 abstract "Non-small cell lung cancer (NSCLC) is relatively insensitive to chemotherapy. NP [vinorelbine (NVB) + cisplatin] is the standard chemotherapy regimen in clinical treatment; however, its side-effects are intolerable for most patients. In some reports, the TNF-related apoptosis-inducing ligand (TRAIL) can enhance the sensitivity of chemotherapy drugs by inducing apoptosis without toxicity to normal cells. In the present study, we evaluated the antitumor effects of the two drugs (TRAIL and NVB alone or in combination) by inducing apoptosis in vitro and in vivo. Using the human NSCLC cell line (A549) and a BALB/c nude mice model, we observed the cell viability (MTT assay), cell apoptosis [Hoechst staining, Annexin V/propidium iodide (PI) staining assay, immunohistochemical staining, RT-PCR and western blotting] and cell proliferation (soft agar colony formation and cell cycle assay). The results showed that TRAIL and NVB alone inhibited tumor growth both in vivo and in vitro. However, the combination of the two drugs produced a more potent antitumor effect (P<0.05) and caused more severe apoptosis in tumor tissue (P<0.05). The key molecular protein level of the mitochondrial apoptotic pathway (Bax and caspase-3) was further upregulated by the combination of the two drugs (P<0.01) and either drug alone (P<0.05). The mRNA level of Bcl-2 and Bax in the combination group was downregulated and upregulated respectively, when compared with the control group (P<0.01). The combination group of A549 cells also showed lower viability compared with the one drug alone group (P<0.05). Moreover, the Hoechst staining assay and Annexin V/PI staining assay showed that the combination of the two drugs induced a more potent apoptosis than either drug alone (P<0.05, early apoptosis P<0.01, respectively). In addition, the cell colony numbers were deduced after treatment with TRAIL or NVB alone (P<0.05) and the two drug combination (P<0.01). Cell cycle analysis showed that TRAIL and NVB alone markedly increased the percentage of cells in G1 phase (P<0.05) and the combination of the two drugs decreased the percentage of cells in G2 and S phase (P<0.05). Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by affecting the level of key signaling protein expression of the apoptosis pathway." @default.
• W2017990112 created "2016-06-24" @default.
• W2017990112 creator A5010562628 @default.
• W2017990112 creator A5035321872 @default.
• W2017990112 creator A5059392900 @default.
• W2017990112 creator A5076774007 @default.
• W2017990112 creator A5078272950 @default.
• W2017990112 date "2014-07-11" @default.
• W2017990112 modified "2023-10-01" @default.
• W2017990112 title "TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer" @default.
• W2017990112 cites W1484817497 @default.
• W2017990112 cites W1967370773 @default.
• W2017990112 cites W1973109581 @default.
• W2017990112 cites W1975111876 @default.
• W2017990112 cites W1987506447 @default.
• W2017990112 cites W1991199427 @default.
• W2017990112 cites W1995741673 @default.
• W2017990112 cites W2000947811 @default.
• W2017990112 cites W2016172589 @default.
• W2017990112 cites W2020439083 @default.
• W2017990112 cites W2037139573 @default.
• W2017990112 cites W2042409437 @default.
• W2017990112 cites W2047972729 @default.
• W2017990112 cites W2053301688 @default.
• W2017990112 cites W2101922134 @default.
• W2017990112 cites W2106284224 @default.
• W2017990112 cites W2106787323 @default.
• W2017990112 cites W2108902725 @default.
• W2017990112 cites W2117692326 @default.
• W2017990112 cites W2130988210 @default.
• W2017990112 cites W2155537385 @default.
• W2017990112 cites W2323955045 @default.
• W2017990112 cites W2399557072 @default.
• W2017990112 doi "https://doi.org/10.3892/or.2014.3324" @default.
• W2017990112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25017445" @default.
• W2017990112 hasPublicationYear "2014" @default.
• W2017990112 type Work @default.
• W2017990112 sameAs 2017990112 @default.
• W2017990112 citedByCount "6" @default.
• W2017990112 countsByYear W20179901122014 @default.
• W2017990112 countsByYear W20179901122015 @default.
• W2017990112 countsByYear W20179901122019 @default.
• W2017990112 countsByYear W20179901122020 @default.
• W2017990112 countsByYear W20179901122022 @default.
• W2017990112 crossrefType "journal-article" @default.
• W2017990112 hasAuthorship W2017990112A5010562628 @default.
• W2017990112 hasAuthorship W2017990112A5035321872 @default.
• W2017990112 hasAuthorship W2017990112A5059392900 @default.
• W2017990112 hasAuthorship W2017990112A5076774007 @default.
• W2017990112 hasAuthorship W2017990112A5078272950 @default.
• W2017990112 hasBestOaLocation W20179901121 @default.
• W2017990112 hasConcept C190283241 @default.
• W2017990112 hasConcept C2775934118 @default.
• W2017990112 hasConcept C2776694085 @default.
• W2017990112 hasConcept C2778239845 @default.
• W2017990112 hasConcept C2780350996 @default.
• W2017990112 hasConcept C2780783641 @default.
• W2017990112 hasConcept C29537977 @default.
• W2017990112 hasConcept C31573885 @default.
• W2017990112 hasConcept C502942594 @default.
• W2017990112 hasConcept C53227056 @default.
• W2017990112 hasConcept C54355233 @default.
• W2017990112 hasConcept C55493867 @default.
• W2017990112 hasConcept C62112901 @default.
• W2017990112 hasConcept C86803240 @default.
• W2017990112 hasConcept C88634738 @default.
• W2017990112 hasConcept C98274493 @default.
• W2017990112 hasConceptScore W2017990112C190283241 @default.
• W2017990112 hasConceptScore W2017990112C2775934118 @default.
• W2017990112 hasConceptScore W2017990112C2776694085 @default.
• W2017990112 hasConceptScore W2017990112C2778239845 @default.
• W2017990112 hasConceptScore W2017990112C2780350996 @default.
• W2017990112 hasConceptScore W2017990112C2780783641 @default.
• W2017990112 hasConceptScore W2017990112C29537977 @default.
• W2017990112 hasConceptScore W2017990112C31573885 @default.
• W2017990112 hasConceptScore W2017990112C502942594 @default.
• W2017990112 hasConceptScore W2017990112C53227056 @default.
• W2017990112 hasConceptScore W2017990112C54355233 @default.
• W2017990112 hasConceptScore W2017990112C55493867 @default.
• W2017990112 hasConceptScore W2017990112C62112901 @default.
• W2017990112 hasConceptScore W2017990112C86803240 @default.
• W2017990112 hasConceptScore W2017990112C88634738 @default.
• W2017990112 hasConceptScore W2017990112C98274493 @default.
• W2017990112 hasIssue "3" @default.
• W2017990112 hasLocation W20179901121 @default.
• W2017990112 hasLocation W20179901122 @default.
• W2017990112 hasOpenAccess W2017990112 @default.
• W2017990112 hasPrimaryLocation W20179901121 @default.
• W2017990112 hasRelatedWork W2367461549 @default.
• W2017990112 hasRelatedWork W2383356456 @default.
• W2017990112 hasRelatedWork W2387887448 @default.
• W2017990112 hasRelatedWork W2389044443 @default.
• W2017990112 hasRelatedWork W2389461974 @default.
• W2017990112 hasRelatedWork W2410520497 @default.
• W2017990112 hasRelatedWork W2418623306 @default.
• W2017990112 hasRelatedWork W2607469626 @default.
• W2017990112 hasRelatedWork W2773240317 @default.
• W2017990112 hasRelatedWork W4306969044 @default.

• next